AgingResearch.NewsJoin free

Phase 3Not yet recruiting

A Study Evaluating Aprocitentan Tablets(SYH9108) for the Treatment of Resistant Hypertension

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Aprocitentan Tablets in the Treatment of Resistant Hypertension

Sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (Industry)
Enrollment
382 planned
Conditions
Resistant Hypertension
Interventions
Aprocitentan tablets(SYH9108); Placebo
Ages
adults, older adults
Registry
NCT07635914

Full record on ClinicalTrials.gov

From the registry

Aprocitentan tablets are currently the only endothelin dual receptor antagonist approved internationally for the treatment of resistant hypertension.This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to evaluate the efficacy and safety of aprocitentan tablets(SYH9108) in patients with treatment-resistant hypertension (rHTN)

Primary outcomes

  • Change from baseline in Sitting Systolic Blood Pressure (SiSBP) after 8 weeks of treatment.

History

  1. Study completion expected

  2. Primary completion expected

  3. Registered

  4. Started